An eye on equity: faricimab-driven health equity improvements in diabetic macular oedema using a distributional cost-effectiveness analysis from a UK societal perspective

Background/Objectives Diabetic macular oedema (DMO) is a leading cause of blindness in developed countries, with significant disease burden associated with socio-economic deprivation. Distributional cost-effectiveness analysis (DCEA) allows evaluation of health equity impacts of interventions, estim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Eye (London) 2024-07, Vol.38 (10), p.1917-1925
Hauptverfasser:	Meunier, Aurelie, Opeifa, Oyin, Longworth, Louise, Cox, Oliver, Bührer, Christian, Durand-Zaleski, Isabelle, Kelly, Simon P., Gale, Richard P.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/1807/1447 692/699/3161 692/700/3934 Angiogenesis Inhibitors - economics Angiogenesis Inhibitors - therapeutic use Bevacizumab Bevacizumab - economics Bevacizumab - therapeutic use Cost analysis Cost-Benefit Analysis Cost-Effectiveness Analysis Developed countries Diabetes Diabetes mellitus Diabetic Retinopathy - drug therapy Diabetic Retinopathy - economics Drug Costs Economics Edema Female Health care Health disparities Health Equity - economics Humans Intravitreal Injections Laboratory Medicine Macular Edema - drug therapy Macular Edema - economics Male Medicine Medicine & Public Health Middle Aged Ophthalmology Opportunity costs Pharmaceutical Sciences/Technology Quality-Adjusted Life Years Ranibizumab - administration & dosage Ranibizumab - economics Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - economics Recombinant Fusion Proteins - therapeutic use Socioeconomics Surgery Surgical Oncology United Kingdom Vascular Endothelial Growth Factor A - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!